2016, Number 4
Angioedema hereditario y su manejo actual
Language: Spanish
References: 44
Page: 91-103
PDF size: 203.30 Kb.
ABSTRACT
Hereditary angioedema is a primary immune deficiency of the complement system, of genetic origin, caused by alteration of the gene that encodes the inhibitor protein C1 esterase activated. It is characterized by recurrent episodes of angioedema of the skin, mucous and submucosal tissues and can affect any part of the body; typically it involves the extremities, face, airway and digestive tract. Abdominal pain associated with angioedema can be confused with an acute abdomen when there is no diagnosis of the disease and lead to unnecessary surgery. The laryngeal edema represents a risk to the life of the patient because it can cause death by suffocation. In women, the hormonal changes seem to have a strong impact on the disease, it is important that doctors know what to do when a patient is pregnant. Some professionals have ignorance of the disease and no access to treatment. Recently the therapeutic approach is directed to prevent the production of bradykinin or inhibit its function to block the function of its B2 receptor. At present, the drugs approved internationally for the effective treatment of this affection are Berinert P and Icatiban.REFERENCES
Bousfiha AA, Jeddane L, Ailal F, Al Herz W, Conley ME, Cunningham-Rundles C, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol [Internet]. 2013 [citado 12 Abr 2015];33(6):1078-87. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23657403
Velasco Medina AA, Cortés Morales G, Barreto Sosa A, Velázquez-Sámano G. Fisiopatología y avances en el tratamiento del angioedema hereditario. Rev Alergia Mex [Internet]. 2011 [citado 12 Abr 2015];58(2):112-119. Disponible en: http://www.imbiomed.com.mx/1/1/articulos.php?method=showDetail&id_articulo=80627&id_seccion=66&id_ejemplar=7970&id_revista=12
Zanichelli A, Arcoleo F, Pina Barca M, Borelli P, Bova M, Cancian M, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis [Internet]. 2015 [citado 12 Abr 2016];10:11. Disponible en: https://ojrd.biomedcentral.com/articles/10.1186/s13023-015-0233-x
Farkas H, Csuka D, Gács J, Cazaller I, Zotter Z, Füst G, et al. Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency. Clin Immunol [Internet]. 2011 [citado 12 Abr 2015]; 141(1):58-66. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21636327
Ferrari Acosta MG, Amoroso Cosimini LE. Evaluación perioperatoria de una paciente con un angioedema grave para una cirugía de coordinación. Anest Analg Reanim [Internet]. 2013 [citado 12 Abr 2015];26(1):[aprox. 14 p.]. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-12732013000100008
Rodrigues Miranda A, Fusel de Ue AP, Vilarinho Sabbag DV, Furlani WJ, De Souza PK, et al. Angioedema hereditário tipo III (estrógeno-dependente): relato de três casos e revisão da literatura. An Bras Dermatol [Internet]. 2013 [citado 2 May 2016];88(4):[aprox. 11 p.]. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962013000400578
Navarro Ruiz A, Crespo Diz C, Poveda Andrés JL, Cebollero de Torre A. Algoritmo de diagnóstico y tratamiento del angioedema hereditario como herramienta para su manejo. Farm Hosp [Internet]. 2013 [citado 12 Abr 2015];37(6):521-529. Disponible en: http://scielo.isciii.es/pdf/fh/v37n6/12articuloespecial02.pdf
Pérez Alonso AJ, Del Olmo Rivas C, Ruiz García VM, Pérez Ramón JA, Jiménez Ríos JA. Angioedema hereditario: causa rara de dolor abdominal. Cir Esp [Internet]. 2012 [citado 12 Abr 2015];90(4):[aprox. 3 p.]. Disponible en: http://www.elsevier.es/es-revista-cirugia-espanola-36-articulo-angioedema-hereditario-causa-rara-dolor-S0009739X11001540?redirectNew=true
Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol [Internet]. 2012 [citado 29 Sept 2015];129(2):308-320. Disponible en: http://www.jacionline.org/article/S0091-6749%2811%2901830-6/pdf
Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1- inhibitor deficiency: consensus report of an International Working Group. Allergy [Internet]. 2012 [citado 12 Abr 2015];67(2): 147-57. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22126399
Cicardi M, Craig TJ, Martinez-Saguer I, Hébert J, Longhurst HJ. Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol [Internet]. 2013 [citado 12 Abr 2015];161(Supl 1):3-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23689238
Zuraw BL, Banerji A, Bemstein JA, Busse PJ, Christiansen SC, Davis-Lorton M, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Imunol Pract [Internet]. 2013 [citado 2 Sept Abr 2015];1(5):458-67. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24565617
Malbrán A, Malbrán E, Menéndez A, Fernández Romero DS. Angioedema hereditario. Tratamiento del ataque agudo en la Argentina. Medicina (B. Aires) [Internet]. 2014 [citado 2 Sept Abr 2015];74(3):[aprox. 5 p.]. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802014000300003
Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol [Internet]. 2014 [citado 12 Abr 2016];112(2):163-169. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24468257
Prematta MJ, Bewtra AK, Levy RJ, Wasserman RL, Jacobson KW, Machnig T, et al. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther [Internet]. 2012 [citado 12 Abr 2015];29(10):913-22. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23054691
Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Reshef A, et al. Results from FAST-3: A phase III randomized, double-blind, placebo-controlled, multicenter study of subcutaneous icatibant in patients with acute hereditary angioedema (HAE) attacks. J Allergy Clin Immunol [Internet]. 2011 [citado 2 Sept Abr 2015];127(2):[aprox. 2 p.]. Disponible en: http://www.jacionline.org/article/S0091-6749%2811%2900040-6/pdf
Lumry WR, Bernstein JA, Li HH, Macginnitie AJ, Riedl M, Soteres DF, et al. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc [Internet]. 2013 [citado 16 Ene 2016];34(2):155-61. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23484891
Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol [Internet]. 2011 [citado 12 Abr 2015];107(6):529-37. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22123383